reports
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Njål Kleiven
- Stian Wibstad
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Martin Mauseth
- Njål Kleiven
- Stian Wibstad
TGS and Viridien Announce Megabar Extension Phase I Multi-client Proje...
TGS and Viridien Announce Megabar Extension Phase I Multi-client Project Offshore Brazil OSLO, Norway (4 September 2025) – TGS, a global leader in energy data and intelligence, in collaboration with joint venture partner Viridien, an advanced technology, digital and earth data company, today announced the commencement of the Megabar Extension Phase I survey in the Barreirinhas Basin offshore Northern Brazil. The 5,300 sq km multi-client 3D seismic survey will be acquired by TGS and imaged by Viridien and builds on Viridien’s Megabar survey coverage. The Barreirinhas Basin features proven...
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Eval...
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Media ReleaseCOPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in an outpatient setting Results showed that 92% of patients with R/R DLBCL received the first full dose of epcoritamab monotherapy in an outpatient settingAdverse event profile and efficacy...
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
TGS Vesting Under the 2022 Long-term Incentive Plan
TGS Vesting Under the 2022 Long-term Incentive Plan Oslo, Norway (1 September 2025) – Reference is made to the stock exchange announcement on 11 August 2025 published by TGS regarding vesting of Performance Stock Units (PSUs) and Restricted Stock Units (RSUs). The vesting of PSUs and RSUs granted by TGS in 2022 in accordance with the terms of the 2022 Long Term Incentive Plan resulted in the right for a total of 83 participants to request the issuance of an aggregate of up to 288,177 shares of TGS common stock pursuant to free-standing warrants subscribed by the participant at the time of ...
TGS ASA – New Share Capital Registered
TGS ASA – New Share Capital Registered Oslo, Norway (1 September 2025) - Reference is made to the stock exchange announcement by TGS ASA (OSE: TGS) (the "Company") on 11 August 2025 regarding vesting of Performance Stock Units (PSUs) and Restricted Stock Units (RSUs). Because of the vesting announced on 11 August 2025, TGS has issued 198,926 new shares. The share capital increase related to the vesting has today been registered with the Norwegian Register of Business Enterprises. Following the capital increase TGS' new share capital is NOK 49,149,936.50 divided into 196,599,746 shares, eac...
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
- ABGSC Oil & Oil Services Research
- John Olaisen
- ABGSC Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- John Olaisen
- Stian Wibstad
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd An...
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; August 26, 2025 (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York City, NY at 7:45 AM EDT (1:45 PM CEST) on September 9, 2025. A webcast of the fireside chat will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company with a co...
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Se...
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) Media ReleaseCOPENHAGEN, Denmark; August 26, 2025 Breakthrough Therapy Designation granted to Rina-S for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapyRegulatory decision supported by data from the Phase 1/2 RAINFOL™-01 trial showing encouraging responses in heavily pretreated EC patientsiRina-S continues to be ev...
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
- ABGSC Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- John Olaisen
- Stian Wibstad
- ABGSC Energy Research
- Daniel Vårdal Haugland
- John Olaisen
- Lars Trongaard Brattli
- Njål Kleiven
- Oliver Dunvold
- Stian Wibstad
- ABGSC Energy Research
- Åsne Holsen
- Daniel Vårdal Haugland
- John Olaisen
- Stian Wibstad
TGS Awarded Large Streamer Contract Offshore Indonesia
TGS Awarded Large Streamer Contract Offshore Indonesia OSLO, Norway (25 August 2025) – TGS, a leading provider of energy data and intelligence, is pleased to announce the award of a large streamer contract offshore Indonesia, covering approximately 10,000 square kilometers. Much of the project will focus on acquiring 3D seismic data for exploration purposes, with the final phase of approximately one month dedicated to 4D seismic data acquisition for production monitoring. The survey is scheduled to commence in Q4 2025 and will span an estimated total duration of approximately eight month...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.